glp-1 crohn's disease ADJUNCTIVE RECEPTOR AGONISTS IN DISEASE: REDUCED STEROID DEPENDENCE AND HOSPITALIZATIONS IN A REAL-WORLD MULTI-NETWORK COHORT Pharmacological interventions for obesity in
Description
Expert discovery in the MDL is set to close in March 2026, with bellwether trials expected later this year
S., Luthra, S., Tanvir, F., Kaur, Y., Singla, A., & Kaur, M
Colosimo, S
Muscle-strengthening activity is tied to a 10 to 17 percent lower risk of dying from any cause, plus lower rates of heart disease, cancer, and diabetes (Momma et al., 2022)
The timeline to resolution is typically shorter because there are fewer metabolic factors in play
Despite the lack of research on tirzepatide, especially in HF patients, its cardiovascular effects indicate potential benefits for this population
